Comparisons of results for the T-SPOT.TB and QFT-GIT assays, where both tests were undertaken, according to region of origin and presence of diagnosed co-morbidities
| QFT-GIT | QFT-GIT | QFT-GIT | |
| Positive | Negative | Indeterminate | |
| African without co-morbities* (n=263) | |||
| T-SPOT.TB positive | 15 (6%) | 3 (1%) | 0 (0%) |
| T-SPOT.TB negative | 6 (2%) | 171 (65%) | 28 (11%) |
| T-SPOT.TB inconclusive | 3 (1%) | 32 (12%) | 5 (2%) |
| African with co-morbities† (n=90) | |||
| T-SPOT.TB positive | 10 (11%) | 1 (1%) | 0 (0%) |
| T-SPOT.TB negative | 2 (2%) | 37 (41%) | 31 (34%) |
| T-SPOT.TB inconclusive | 0 (0%) | 6 (7%) | 3 (3%) |
| Asian‡ (n=106) | |||
| T-SPOT.TB positive | 6 (6%) | 2 (2%) | 0 (0%) |
| T-SPOT.TB negative | 1 (1%) | 81 (76%) | 3 (3%) |
| T-SPOT.TB inconclusive | 2 (2%) | 11 (10%) | 0 (0%) |
Diagnosed co-morbidities included malaria, hepatitis or helminth infection (schistosomiasis/strongyloides).
An inconclusive T-SPOT.TB result was one that was either indeterminate or where the test was not completed.
Comparisons are based on the McNemar test for paired proportions of T-SPOT.TB vs QFT-GIT:
↵* Proportions positive: 7% vs 9%, p=0.1. Proportions not completed or indeterminate: 15% vs 13%, p=0.4.
↵† Proportions positive: 12% vs 13%, p>0.9. Proportions not completed or indeterminate: 10% vs 38%, p=0.0001.
↵‡ Proportions positive: 8% vs 8%, p>0.9. Proportions not completed or indeterminate: 12% vs 3%, p=0.02.